
Release date: 2025-03-13 10:56:23 Article From: Lucius Laos Recommended: 215
To explore the price of eltrombopag and its role in the treatment of specific diseases to provide a reference for patients.
The price of eltrombopag as a drug used to treat specific blood disorders is a concern for many patients.
Eltrombopag's pricing is influenced by a variety of factors, including R&D costs, production costs, market demand and competitive conditions. Pharmaceutical companies use these factors to determine the final market price.
Due to the differences in medical policies and insurance coverage in different countries, the price of eltrombopag varies significantly around the world. For example, in some countries, the drug may be included in the reimbursement list of medical insurance, thereby reducing the financial burden on patients; In other areas, the cost is higher.
In addition to obtaining drugs directly from hospital pharmacies, some patients also choose to reduce their drug costs through online pharmacies or cross-border purchases. However, caution should be taken when choosing this option to ensure that the drug is responsibly sourced and meets local regulatory requirements.
Understanding the mechanism of action of eltrombopag and its indications is essential for proper medication.
Eltrombopag is primarily used to treat thrombocytopenic purpura (ITP) and other specific types of thrombocytopenia. However, not all patients are suitable for this medicine, and doctors will determine whether it is suitable for the patient's specific situation.
During medication, routine blood tests should be performed regularly to monitor platelet counts and dose adjustments accordingly. At the same time, pay attention to possible side effects, such as abnormal liver function, and report to the doctor in time and adjust the treatment plan.
It is equally important for patients who need to take eltrombopag for a long time to establish a healthy lifestyle. This includes eating a balanced diet, exercising moderately, and avoiding exposure to activities that may increase the risk of bleeding.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1062025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3822024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:962025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1202025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1112025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1282025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1222025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1222025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: